neurological or psychiatric disorders Harms: NR Modifiers: NR C-198 Table C-1. Evidence table, continued Study Description Intervention Inclusion/ Exclusion Criteria/ Population Baseline Measures* Outcomes Author: Aman et al. 2009 35-38 Country: US Intervention setting: Clinic, home Enrollment period: NR Funding: NIMH Design: RCT Note: See earlier study 87 reporting on this population in 2011 AHRQ review 9 Intervention: Risperidone (0.5 to 3.5 mg/day) or aripiprazole if risperidone was ineffective ((aripiprazole started at 2 mg and adjusted up to 15 mg) or a combination of medication plus parent training. Parents of children in combination group received an average of 11.4 parent training sessions. Assessments: Home Situations Questionnaire (HSQ), Aberrant Behavior Checklist-Irritability (ABC- I), Vineland Adaptive Behavior Scales (VABS), Noncompliance index. Assessed weekly for 8 weeks then every 4 weeks until week 24. Follow-up study at 1 year Groups: G1: risperidone G2: risperidone + parent training Co-interventions held stable during treatment: Yes Frequency of contact Inclusion criteria: • age between 4 and 14 years • DSM-IV-TR diagnosis of autistic disorder, Asperger’s disorder, or PDD-NOS based on clinical assessment and corroborated by the ADI-R • serious behavioral problems (e.g tantrums, aggression and self-injury) evidenced by score ≥ 18 on ABC-Irritability subscale and CGI- severity score ≥ 4 • IQ ≥ 35 or mental age of 18 months from Stanford-Binet 5, Leiter International Performance Scale or Mullen Scales of Early Learning • anticonvulsant treatment permissible if medication was stable (≥ 4 wks) and subject was seizure free (≥ 18 mos) Exclusion criteria: • significant medical condition by history, HSQ, mean ± SD: Average severity score G1: 4.16 ± 1.47 G2: 4.31 ± 1.67 “Yes” count G1: 18.9 ± 3.46 G2: 18.6 ± 4.65 ABC, mean ± SD: Irritabilty G1: 29.7 ± 6.10 G2: 29.3 ± 6.97 Social withdrawal G1: 17.1 ± 8.37 G2: 15.2 ± 9.01 Stereotypic behavior G1: 10.6 ± 5.46 G2: 7.59 ± 5.20 Hyperactivity/non compliance G1: 36.1 ± 6.86 G2: 35.3 ± 9.30 Inappropriate speech G1: 6.37 ± 4.03 G2: 5.75 ± 3.43 VABS, mean ± SD: Standard Score Daily living skills G1: 41.14 ± 19.81 G2: 50.79 ± 18.49 24 Week Follow - Up VABS, mean ± SD: Standard Score Daily living skills G1: 45.34 ± 20.48 G2: 55.65 ± 21.86 Socialization G1: 56.59 ± 17.38 G2: 67.42 ± 18.48 Communication G1: 53.57 ± 20.23 G2: 63.90 ± 22.65 Adaptive Composite G1: 47.84 ± 15.81 G2: 57.87 ± 19.03 Age Equivalent Score Daily living skills G1: 3.49 ± 1.72 G2: 4.36 ± 2.25 Socialization G1: 2.71 ± 1.51 G2: 3.99 ± 2.56 Communication G1: 3.42 ± 2.18 G2: 4.58 ± 2.85 Adaptive Composite G1: 12.88 ± 10.83 G2: 8.41 ± 8.69 One Year Follow-up** C-199 during study: ~weekly across groups Concomitant therapies, n (%): NR N at enrollment: G1: 49 G2: 75 N at follow-up (1 year): G1: 36 G2: 51 exam or lab test • lifetime diagnosis of psychosis, bipolar disorder or current diagnosis of major depression, obsessive-compulsive disorder, substance abuse, or girls with positive Beta HCG pregnancy test